New cocktail of drugs aims to fight tough esophageal cancer
NCT ID NCT07481058
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new oral drug called KC1036 combined with standard immunotherapy (toripalimab) and chemotherapy (paclitaxel and cisplatin) as a first treatment for advanced esophageal cancer that has spread or come back. The trial will enroll 60 adults aged 18-75 who have not had prior treatment for their advanced disease. The main goal is to see how many patients' tumors shrink or disappear, while also monitoring safety and how long the benefits last.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KC1036 (oral drug) combined with toripalimab (immunotherapy), paclitaxel, and cisplatin (chemotherapy)
What this could lead to
If successful, this combination could offer a new first-line treatment option for advanced esophageal cancer, potentially shrinking tumors and delaying disease progression.
What could go wrong
This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The combination of drugs may cause significant side effects, and there is no guarantee it will work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••